ASX:NOX
Market Cap:
Price Delay ~20min
Interactive 2020
Annual Report

Media

22-Mar-2021

Australian digital pharmaceutical news site, Health Industry Hub reported, "Noxopharm and BMS immuno-oncology trial proceeds to patient recruitment"

Read more here.

23-Feb-2021

In its conference data report for the ASCO Genitourinary Cancers Symposium, BioWorld reported on Noxopharm.

Read more here.

12-Feb-2021

Bloomberg Business reported, “Noxopharm Shares Major Cancer Survival Benefit at ASCO Global Conference”.

Read more here.

11-Feb-2021

PharmaVOICE.com, the digital resource for life-sciences executives and other healthcare-service related professionals provided the following.

Read more here.

11-Feb-2021

Digital hub for Life Science industry news, BioSpace, shared the following release after the ASCO GU Cancers Symposium.

Read more here.

9-Feb-2021

Biotech Dispatch, a news site dedicated to the breaking news and commentary about the Australian biotechnology and Life Sciences sector reported.

Read more here.

14-Jan-2021

Australian pharmaceutical industry news site, Health Industry Hub also reports, "Australia's Noxopharm advances NOXCOVID study".

Read more here. 

13-Jan-2021

The West Australian Newspaper reported today on Noxopharm's announcement that its European NOXCOVID trial in COVID-19 patients has been cleared to administer to the fifth and final dosage cohort.

Read more here. 

13-Jan-2021

Business News Australia reported that Noxopharm's COVID-19 treatment trial advances to the final stage.

Read more here.

13-Jan-2021

The Market Herald reported, "Noxopharm (ASX:NOX) cleared to up dosage in COVID study

Read more here.